Related Experiment Video

Updated: Apr 17, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.9K

Everolimus in diffuse large B-cell lymphomas

Michele Merli1, Andrea Ferrario, Margherita Maffioli

  • 1Division of Hematology, University Hospital Ospedale di Circolo & Fondazione Macchi, Viale L Borri 57, 21100 Varese, Italy.

Future Oncology (London, England)
|February 13, 2015
PubMed

Insights

Everolimus shows promise for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This mTOR inhibitor demonstrated significant activity and good tolerability, both alone and in combination with rituximab.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) presents challenges in relapsed/refractory settings.
  • The mechanistic target of rapamycin (mTOR) pathway is frequently dysregulated in DLBCL.
  • Novel therapeutic strategies targeting the mTOR pathway are needed for DLBCL treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of everolimus, an oral mTOR inhibitor, in patients with relapsed/refractory DLBCL.
  • To assess the combination of everolimus with rituximab in this patient population.

Main Methods:

  • A large Phase II study investigated everolimus at a 10 mg daily dose in relapsed/refractory DLBCL.
  • Preclinical studies informed the selection of everolimus and its dosing.
  • Combination therapy with rituximab was also evaluated.

Main Results:

  • Everolimus monotherapy achieved a 30% overall response rate in relapsed/refractory DLBCL.
  • The primary toxicity observed with everolimus was thrombocytopenia.
  • The combination of everolimus and rituximab demonstrated an objective response rate of 38% with a 13% complete response rate, without increased toxicity.

Conclusions:

  • Everolimus exhibits substantial activity and good tolerability in relapsed/refractory DLBCL.
  • The combination of everolimus and rituximab shows encouraging efficacy in DLBCL.
  • Further investigations of everolimus in combination therapies for DLBCL are warranted.
Keywords:
diffuse large B-cell lymphomaeverolimusmTOR pathwayrapamycin analogs

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
732
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
685
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
414
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K